Íslenska
Search
My pages
Close

Greinasafn

08. What is the meaning of the red warning triangle?

07. How long is there an obligation to create and submit PSURs or RMPs after a marketing authorisation was withdrawn?

06. How long is there an obligation to continue collection and submission of spontaneous ADR reports after a marketing authorisation of the suspect product was withdrawn?

05. Are Marketing Authorisation Holders required to have a Local Contact Person for Pharmacovigilance in Iceland?

04. Are Marketing Authorisation Holders required to have a Qualified Person for PharmacoVigilance (QPPV) residing in Iceland?

03. Does IMA require literature reports for Icelandic cases? Should a copy of the literature article be attached?

02. Is there a list of local literature that the Marketing Authorisation Holders should monitor?

01. What happens to ICSRs received by IMA from healthcare professionals and the public?

How can we help?

LiveChat